![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, October 17, 2014 1:18:17 PM
WASHINGTON -- President Obama's new Ebola 'czar,' Ron Klain, has an extensive resume at the top levels of politics and government -- if not in battling infectious diseases.
He was the chief of staff for two vice presidents -- Joe Biden and Al Gore -- and one attorney general, Janet Reno. He also served as a senior White House aide to President Obama.
After leaving the White House for the private sector in 2011, Klain became a partner in the Washington lobbying firm of O'Melveny & Myers LLP. He was not himself a registered lobbyist, however, which means the White House ban on hiring lobbyist doesn't apply.
...
Case said Klain would take a leave of absence and planned to return to his company. "Ron is a talented manager and a wise counselor who understands government, business, and the non-profit sectors," Case said in a statement. "We look forward to welcoming him back soon."
As Biden's chief of staff, Klain had a key role in implementing the American Recovery and Reinvestment Act of 2009 -- and signed off on one of its most controversial projects: a $535 million loan guarantee to solar panel maker Solyndra.
"Sounds like there are some risk factors here -- but that's true of any innovative company that POTUS would visit," Klain wrote to Department of Energy officials on May 24, 2010, a day before Obama visited a company factory. "It looks like it is OK to me, but if you feel otherwise, let me know."
http://www.usatoday.com/story/news/politics/2014/10/17/ron-klain-bio-resume-recount-stimulus-ebola-czar/17430563/
The union guys say, "Si se puede..."...we are saved! You can rest assured, throwing money at the problem won't be an object with the new Czar. Fired up, ready to go!
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM